SAFE Fertility Clinic’s Research at ASPIRE 2026 – Why Every 1-Mb Detail from PGTseq-A Matters for Your Success
A team of embryologists from SAFE Fertility Clinic and Next Generation Genomic Co., Ltd., led by Dr. Wiwat Quangkananurug, Founder and CEO of SAFE Fertility Group PCL., was honored to present their latest technology in high-resolution embryo screening—PGTseq-A—at the 15th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2026) in Beijing, China.
This success reinforces SAFE Fertility Clinic’s commitment to advancing reproductive technology, dedicated to developing advanced solutions that maximize the chances of a healthy pregnancy for every family.
PGTseq-A: Higher Precision for Better Choices
In the world of fertility treatments, PGT-A (Preimplantation Genetic Testing for Aneuploidy) is the "gold standard" used to screen embryos for chromosomal health before transfer. It is a vital step for patients undergoing IVF/ICSI to increase pregnancy rates and reduce the risk of miscarriage. However, standard PGT-A technologies often have limitations in detecting very small chromosomal changes, known as "Small CNVs," which can impact long-term development.
To overcome these limits, SAFE Fertility Clinic and Next Generation Genomic Co., Ltd. utilize PGTseq-A—a targeted screening system with much higher resolution than standard methods. The research presented at this international congress demonstrates that PGTseq-A was able to flag a CNV as small as 1 Mb (1 Megabase) in this case. This level of detail allows scientists and doctors to identify specific issues more accurately, providing couples with the comprehensive data they need to make confident decisions for a successful pregnancy.
Proven Success: A Real-Life Case Study in Accuracy
The research highlighted a significant case where the team detected a recurring abnormality in 2 out of 4 embryos from the same couple. By identifying a tiny duplication on Chromosome 17 and utilizing Microarray technology, used here to confirm the finding, the scientists were able to cross-reference the embryos' DNA with that of the parents. They discovered that this specific trait was inherited from the father and was determined to be a benign inherited variant unlikely to affect the child’s health.
This deep, multi-layered analysis ensures that couples do not lose the opportunity to use a healthy embryo simply due to low-resolution test results. It provides the clarity needed to proceed with confidence.
This significant research was made possible by a dedicated team of Thai fertility specialist and scientists committed to raising the bar for reproductive care on the global stage:
- Patthorn Jaikla
- Wanwisa Suksalak
- Sirikul Kulanuwat
- Sunanta Nabu
- Wipawee Tangsee
- Chutimon Pomsuwan
- Nadsarin Tochoowong
- Sujin Chanchamroen – Chief Laboratory Officer, SAFE Fertility Group PCL.
- Wiwat Quangkananurug, M.D. – Founder and CEO, SAFE Fertility Group PCL.
SAFE Fertility Group and Next Generation Genomic remain dedicated to bringing world-class innovation to patient care. We believe that every small detail in an embryo is a giant leap toward building a complete and healthy family.